Question 1

What do these compounds have in common?

Accepted Answer

The compounds people line up next to tesamorelin are grouped by what they are thought to do, not by what has been measured in each of them. A 2026 orthopaedic review puts them in a single sentence, describing growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF-1 signaling and satellite cell repair. A secretagogue is anything that prompts a gland to release a hormone it already makes, and IGF-1 is the blood marker that goes up when growth hormone output does. The same review then states what sits behind the whole group, recording a current lack of clinical trials. So the list is a shared hypothesis about a pathway rather than a shared set of results. Tesamorelin belongs to it on mechanism and sits apart from it on evidence, and that split runs through every question below.

Question 2

How do tesamorelin and ipamorelin differ in what has been measured?

Accepted Answer

Put the two records beside each other and they are not the same kind of object. A 2026 meta-analysis records that five RCTs evaluating Tesamorelin were included in the analysis, and a second 2026 systematic review of the same field counted four RCTs (909 patients). On the ipamorelin side, the closest thing to a measurement among these sources is in animals and it is not of ipamorelin on its own, since a 2026 primer reports that CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss. The same primer adds that these findings are limited to animal studies. Maximum tetanic tension is the peak force a muscle makes under sustained stimulation on a laboratory rig. What is being compared, then, is a blinded human trial programme against a force reading in mice given a steroid, which is a difference in what has been measured at all rather than a difference in the size of an effect. The adverse events those trials recorded have their own page at the Tesamorelin safety page.

Question 3

What will tesamorelin and ipamorelin do together?

Accepted Answer

None of the studies covered here administered the two in one protocol, in people or in animals, so there is no combined result to report. What can be reported is what each half arrives with. A 2026 primer for sports medicine physicians records that tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence, and the only ipamorelin entry in that same review is a murine experiment of the pairing with CJC-1295. The review closes on the group as a whole, noting that information regarding the indications, dosing, frequency, and duration of treatment remains unknown. Read what a combination inherits. It carries the limits of both halves forward, and an approval granted to one molecule for one diagnosis does not travel to whatever is drawn into the same syringe. Expectation and measurement are different things, and only the first is available for this pairing.

Question 4

How long does it take to see results from tesamorelin and ipamorelin?

Accepted Answer

Every published tesamorelin figure is a reading taken at a scheduled visit, and the schedules were long. A 2008 report describes its parent trial in one line, recording that treatment of HIV patients with daily tesamorelin, a growth hormone-releasing factor analogue, for 26 weeks resulted in a significant decrease in visceral adipose tissue (VAT) and improvement in lipids. The liver trial ran twice that, with a year of daily injections followed by a 6-month open-label phase during which all participants received tesamorelin. A 2025 trial in people with HIV read its primary endpoint at six months. Nothing in that record describes a week-by-week course, because the scans were taken at the start and at the end rather than along the way. For ipamorelin there is no interval to quote at all among these sources, since the only experiment they describe ran in mice. So the shortest tesamorelin endpoint covered here is six months, and any shorter timeline a reader meets is somebody's expectation instead of a measurement.

Question 5

Tesamorelin against HGH: what is the actual difference?

Accepted Answer

The difference is where the molecule acts, and it decides what each one needs from the body. A 2011 review describes tesamorelin as a synthetic analogue of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone, endogenous meaning the hormone a body makes for itself. Injected growth hormone supplies that hormone from outside and asks nothing of the pituitary gland. Tesamorelin asks the pituitary for more of it, so its whole action depends on a gland that still works. The second difference is on paper. A companion review from the same year records tesamorelin as the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. Growth hormone holds separate approvals for its own named diagnoses, and what those cover has its own record at the HGH overview. Two approvals, two molecules and two populations do not make either one a stand-in for the other.

Question 6

How does tesamorelin sit next to CJC-1295 and sermorelin?

Accepted Answer

These three are the closest relatives tesamorelin has. An anti-doping lab treats them as one problem. A 2021 method paper set out to study the in vitro metabolism and detection of four of the larger GHRH synthetic analogs (sermorelin, tesamorelin, CJC-1295, and CJC-1295 with drug affinity complex) in fortified urine. That means urine spiked in the lab, not taken from a dosed volunteer. Being caught by one assay means they are chemically alike. It says nothing about whether they do the same thing in a person. On that second question the records come apart. Tesamorelin carries randomised trials with scan endpoints, while a 2026 review puts sermorelin and CJC-1295 in the group it describes as facing a current lack of clinical trials. Chemical family and clinical evidence are different registers, and only one of the two has been filled in here.

Question 7

Does tesamorelin increase IGF-1 the way an IGF-1 analogue does?

Accepted Answer

It raises it, and the more useful question is what the rise is worth. In a 2014 randomised trial, after 12 months, tesamorelin treatment led to a significantly greater increase in IGF-I than did placebo treatment in 39 obese adults with reduced growth hormone output. IGF-1 sits one step below growth hormone, so a rise in it marks the signal arriving rather than an outcome changing. A 2025 trial measured both ends at once and they came apart, reporting that in those participants IGF-1 levels increased, but changes did not correlate with summary regression change score or WC, where WC stands for waist circumference. An IGF-1 analogue such as IGF-1 LR3 skips the two steps above it and supplies the marker itself, and none of the studies covered here has given one to anyone or set it beside tesamorelin. The difference is one of position in a chain rather than of strength, and a marker moving is not the same as a person noticing anything.

Question 8

What is on record for stacking tesamorelin with IGF-1 LR3 or AOD-9604?

Accepted Answer

Stacking questions turn up with a mechanism attached and nothing measured behind them. None of the studies covered here gave tesamorelin together with IGF-1 LR3, with AOD-9604, or with anything else in the group. What the reviews supply is the reason people expect such pairings to work. A 2026 review groups AOD-9604 with ipamorelin, CJC-1295, tesamorelin and sermorelin as compounds that activate IGF-1 signaling and satellite cell repair. The case for putting them together is that they push on one pathway from different points. A second 2026 review says what that reasoning is worth, recording that many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients. A shared pathway predicts a combination rather than measuring one. Adding an unmeasured compound to a measured one does not divide the uncertainty between them.

Question 9

Is tesamorelin the same as Ozempic?

Accepted Answer

No, and the reason matters more than the answer itself. A 2012 review describes tesamorelin as a growth hormone releasing factor analogue approved by the Food and Drug Administration in November 2010, for lipodystrophy associated with HIV infection. Its route runs through the pituitary gland and its approved purpose is a fat distribution problem inside one diagnosis. Ozempic and retatrutide belong to the GLP-1 family, which no source behind this page covers, so what their trials measured is kept at the GLP-1 overview rather than guessed at from here. The endpoints are the sharpest contrast of all. The 2007 tesamorelin trial read its result off a scanner, where the measure of visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group, reported as the percent change from baseline in visceral adipose tissue as shown on computed tomography. That is deep abdominal fat in patients, and a compound tracked that way is answering a different question from one tracked by weighing people.

Question 10

Which of these comparisons rest on a trial, and which on resemblance?

Accepted Answer

Sorted by what exists, the field splits cleanly. Tesamorelin has a randomised programme behind it, and a 2026 meta-analysis pooling that programme reports Tesamorelin was associated with significant reduction in visceral adipose tissue in those patients. Ipamorelin, CJC-1295, sermorelin and AOD-9604 appear in the same reviews as members of a mechanism, with a 2026 review recording a current lack of clinical trials behind the group. MK-677 is not named anywhere among the sources covered here, which means this page can place it in no comparison at all rather than that nothing exists about it elsewhere. Every pairing on this page therefore rests on resemblance, because only one of the two halves has trial data every time. That asymmetry is the single most useful thing to carry away from a comparison involving tesamorelin, and it is itself the finding rather than a gap in the write-up.

Question 11

What outcome does each of these compounds have a number for?

Accepted Answer

Tesamorelin's numbers are body-composition readings taken in one group of patients. A 2026 systematic review reports that Tesamorelin 2mg significantly reduced visceral adipose tissue in those patients. A separate meta-analysis records that it improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy. Hepatic fat means fat inside the liver. For the rest of the group the only number among these sources is the mouse force reading already quoted. The clinical column holds a current lack of clinical trials. Notice which outcomes are missing on both sides of that line. Strength, muscle size, scale weight and anything at all measured in an adult without HIV have no figure attached, for tesamorelin or for its relatives. The amounts those trials assigned, and to whom, are itemised on the Tesamorelin dosage page.

Question 12

What does tesamorelin's approval say about the rest of the group?

Accepted Answer

Nothing at all, and that is the point most often got wrong here. A 2026 review in Sports Medicine takes as its subject the regulatory status of prominent approved and unapproved peptides marketed direct to patients. Its list holds ipamorelin, sermorelin, CJC-1295 and tesamorelin (Egrifta) side by side on one line. Being on the same list does not give them the same status. An approval is a ruling on one filing: one molecule, one maker, one use, one group of patients. A 2026 primer says how far this one reaches, noting that tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence. If it does not reach a second use of the same molecule, it will not reach a second molecule sold beside it. The approval belongs to the injection that earned it.

Question 13

Do any of these show up on the same anti-doping test?

Accepted Answer

They do, and it is one of the few places where the whole group is handled alike. A 2021 validation paper opens by recording that the administration of growth hormone releasing hormone (GHRH) and its synthetic analogs is prohibited by the World Anti-Doping Agency (WADA). The same work notes a gap between the rule and the lab. Although there is evidence of their use, based on admissions and intelligence, they do not appear to have been found in anti-doping samples by WADA accredited laboratories. The method those authors published then reports that limits of detection of the target peptides were generally 1 ng/ml (WADA required performance limit) or less. For anyone subject to testing the point is practical. Tesamorelin, sermorelin and the two CJC-1295 forms sit inside one method rather than behind separate ones, so a sample is not screened for one name at a time.

Question 14

What would a head-to-head comparison actually require?

Accepted Answer

One protocol, one set of participants and a random allocation between arms, which is exactly what the tesamorelin record already contains for tesamorelin against placebo. A 2010 trial shows the shape of it, assigning patients to receive tesamorelin [2 mg subcutaneous (SC) every day] or placebo in a 2:1 ratio, with patients and investigators blinded to treatment assignment throughout the study. Swap the placebo arm for ipamorelin and the question people actually ask would have an answer attached to it. No study among the sources covered here has run that design, against any second compound, for any outcome. Until one does, a comparison involving tesamorelin is two separate records read side by side rather than a contest, and the most honest thing a page can do is say which of the two has been measured and in whom.

Tesamorelin comparisons and stacks